S&P 500   4,974.66 (+0.15%)
DOW   38,006.49 (+0.05%)
QQQ   414.47 (-0.04%)
AAPL   165.18 (+0.11%)
MSFT   396.38 (-0.69%)
META   474.18 (-1.43%)
GOOGL   154.26 (+0.11%)
AMZN   174.68 (+0.03%)
TSLA   140.51 (-4.45%)
NVDA   773.81 (+1.55%)
AMD   146.35 (-0.20%)
NIO   3.83 (+0.79%)
BABA   70.00 (+1.35%)
T   16.37 (-0.85%)
F   12.59 (+3.71%)
MU   106.83 (+0.06%)
GE   149.43 (+0.93%)
CGC   7.66 (-3.40%)
DIS   111.97 (-0.57%)
AMC   3.31 (+4.75%)
PFE   26.31 (+1.19%)
PYPL   62.54 (+0.37%)
XOM   120.36 (+0.40%)
S&P 500   4,974.66 (+0.15%)
DOW   38,006.49 (+0.05%)
QQQ   414.47 (-0.04%)
AAPL   165.18 (+0.11%)
MSFT   396.38 (-0.69%)
META   474.18 (-1.43%)
GOOGL   154.26 (+0.11%)
AMZN   174.68 (+0.03%)
TSLA   140.51 (-4.45%)
NVDA   773.81 (+1.55%)
AMD   146.35 (-0.20%)
NIO   3.83 (+0.79%)
BABA   70.00 (+1.35%)
T   16.37 (-0.85%)
F   12.59 (+3.71%)
MU   106.83 (+0.06%)
GE   149.43 (+0.93%)
CGC   7.66 (-3.40%)
DIS   111.97 (-0.57%)
AMC   3.31 (+4.75%)
PFE   26.31 (+1.19%)
PYPL   62.54 (+0.37%)
XOM   120.36 (+0.40%)
S&P 500   4,974.66 (+0.15%)
DOW   38,006.49 (+0.05%)
QQQ   414.47 (-0.04%)
AAPL   165.18 (+0.11%)
MSFT   396.38 (-0.69%)
META   474.18 (-1.43%)
GOOGL   154.26 (+0.11%)
AMZN   174.68 (+0.03%)
TSLA   140.51 (-4.45%)
NVDA   773.81 (+1.55%)
AMD   146.35 (-0.20%)
NIO   3.83 (+0.79%)
BABA   70.00 (+1.35%)
T   16.37 (-0.85%)
F   12.59 (+3.71%)
MU   106.83 (+0.06%)
GE   149.43 (+0.93%)
CGC   7.66 (-3.40%)
DIS   111.97 (-0.57%)
AMC   3.31 (+4.75%)
PFE   26.31 (+1.19%)
PYPL   62.54 (+0.37%)
XOM   120.36 (+0.40%)
S&P 500   4,974.66 (+0.15%)
DOW   38,006.49 (+0.05%)
QQQ   414.47 (-0.04%)
AAPL   165.18 (+0.11%)
MSFT   396.38 (-0.69%)
META   474.18 (-1.43%)
GOOGL   154.26 (+0.11%)
AMZN   174.68 (+0.03%)
TSLA   140.51 (-4.45%)
NVDA   773.81 (+1.55%)
AMD   146.35 (-0.20%)
NIO   3.83 (+0.79%)
BABA   70.00 (+1.35%)
T   16.37 (-0.85%)
F   12.59 (+3.71%)
MU   106.83 (+0.06%)
GE   149.43 (+0.93%)
CGC   7.66 (-3.40%)
DIS   111.97 (-0.57%)
AMC   3.31 (+4.75%)
PFE   26.31 (+1.19%)
PYPL   62.54 (+0.37%)
XOM   120.36 (+0.40%)
NASDAQ:ZURA

Zura Bio (ZURA) Stock Price, News & Analysis

$3.32
+0.01 (+0.30%)
(As of 11:09 AM ET)
Today's Range
$3.24
$3.49
50-Day Range
$2.05
$4.21
52-Week Range
$2.00
$14.00
Volume
30,473 shs
Average Volume
271,952 shs
Market Capitalization
$143.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.40

Zura Bio MarketRank™ Stock Analysis

Analyst Rating
Buy
3.20 Rating Score
Upside/​Downside
395.5% Upside
$16.40 Price Target
Short Interest
Healthy
3.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.36mentions of Zura Bio in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.00) to ($1.26) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.45 out of 5 stars

Medical Sector

461st out of 907 stocks

Biological Products, Except Diagnostic Industry

73rd out of 154 stocks

ZURA stock logo

About Zura Bio Stock (NASDAQ:ZURA)

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

ZURA Stock Price History

ZURA Stock News Headlines

This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Zura Bio Limited (NASDAQ:ZURA) Short Interest Up 90.4% in March
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Zura Bio GAAP EPS of -$0.18
Zura Bio Ltd. Wt
See More Headlines
Receive ZURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zura Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
4/22/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ZURA
Web
N/A
Fax
N/A
Employees
14
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.40
High Stock Price Target
$22.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+395.5%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

Net Income
$-69,240,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.85 per share

Miscellaneous

Free Float
36,285,000
Market Cap
$142.63 million
Optionable
Not Optionable
Beta
0.55
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. David Brady
    Head of Business Development
  • Dr. Someit Sidhu M.D. (Age 34)
    Founder, CEO & Director
  • Mr. Robert Lisicki (Age 56)
    President & COO
  • Mr. Verender S. Badial (Age 52)
    Chief Financial Officer
  • Dr. Gary Whale Ph.D. (Age 50)
    Chief Technology Officer
  • Dr. Michael D. Howell Ph.D. (Age 46)
    Chief Scientific Officer & Head of Translational Science
  • Ms. Kimberly Ann Davis (Age 56)
    Chief Legal Officer & Secretary
  • Ms. Theresa Lowry (Age 50)
    Chief Human Resources Officer
  • Dr. Kiran Nistala MBBS (Age 51)
    Ph.D., Chief Medical Officer & Head of Development

ZURA Stock Analysis - Frequently Asked Questions

Should I buy or sell Zura Bio stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zura Bio in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZURA shares.
View ZURA analyst ratings
or view top-rated stocks.

What is Zura Bio's stock price target for 2024?

5 brokers have issued twelve-month target prices for Zura Bio's shares. Their ZURA share price targets range from $10.00 to $22.00. On average, they predict the company's share price to reach $16.40 in the next year. This suggests a possible upside of 395.5% from the stock's current price.
View analysts price targets for ZURA
or view top-rated stocks among Wall Street analysts.

How have ZURA shares performed in 2024?

Zura Bio's stock was trading at $4.67 at the beginning of 2024. Since then, ZURA shares have decreased by 29.1% and is now trading at $3.31.
View the best growth stocks for 2024 here
.

Are investors shorting Zura Bio?

Zura Bio saw a increase in short interest in March. As of March 31st, there was short interest totaling 628,300 shares, an increase of 90.4% from the March 15th total of 330,000 shares. Based on an average daily volume of 275,300 shares, the short-interest ratio is presently 2.3 days. Currently, 3.3% of the shares of the stock are sold short.
View Zura Bio's Short Interest
.

When is Zura Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our ZURA earnings forecast
.

How were Zura Bio's earnings last quarter?

Zura Bio Limited (NASDAQ:ZURA) issued its quarterly earnings data on Monday, November, 13th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.07.

How do I buy shares of Zura Bio?

Shares of ZURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ZURA) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners